{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:45:10Z","timestamp":1785883510500,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.107776","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:44:14Z","timestamp":1781300654000},"page":"107776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-141X","authenticated-orcid":false,"given":"J.B.","family":"Aragon-Ching","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"P.","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-5261","authenticated-orcid":false,"given":"H.","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tyroller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.esmoop.2026.107776_bib1","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2026.107776_bib2","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107776_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2026.107776_bib4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, version 1.2025."},{"issue":"6","key":"10.1016\/j.esmoop.2026.107776_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"46","key":"10.1016\/j.esmoop.2026.107776_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008588","article-title":"Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107776_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119313","article-title":"Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies","volume":"10","author":"Sun","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107776_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0448","article-title":"Outcomes among patients with or without obesity and with cancer following treatment with immune checkpoint blockade","volume":"5","author":"Yoo","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107776_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.21873\/anticanres.16159","article-title":"Association between body mass index and outcomes in patients with urothelial carcinoma treated with pembrolizumab","volume":"43","author":"Tomisaki","year":"2023","journal-title":"Anticancer Res"},{"issue":"10397","key":"10.1016\/j.esmoop.2026.107776_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.esmoop.2026.107776_bib12","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/cncr.34918","article-title":"Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer","volume":"129","author":"Leshem","year":"2023","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107776_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009769","article-title":"Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma","volume":"12","author":"Jan","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107776_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"10.1016\/j.esmoop.2026.107776_bib15","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.107776_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102900","article-title":"Individualizing first-line treatment for advanced urothelial carcinoma: a favorable dilemma for patients and physicians","volume":"134","author":"Grande","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107776_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107776_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.eururo.2023.08.001","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: analysis from JAVELIN Bladder 100 by duration of first-line chemotherapy and interval before maintenance","volume":"85","author":"Sridhar","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107776_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104506","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients","volume":"10","author":"Gupta","year":"2025","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107776_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.eururo.2025.05.017","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 Trial in patients with nonvisceral or lymph node-only disease","volume":"88","author":"Bellmunt","year":"2025","journal-title":"Eur Urol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:52:50Z","timestamp":1785880370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926017187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926017187"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107776","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107776"}}